Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,87
KB1,11
PKN107,94108,141,63
Msft401,89401,931,28
Nokia6,2226,2743,92
IBM258,91259,130,29
Mercedes-Benz Group AG59,2959,310,92
PFE27,3227,33-0,16
18.02.2026 17:39:38
Indexy online
AD Index online
select
AD Index online
 

  • 18.02.2026 17:35:11
Arseus (RCUS.BR, Brussels)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
22,95 1,10 0,25 1 859 285
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 18.02.2026
Popis společnosti

Business Summary: Fagron NV, formerly Arseus NV, is a Belgium-based company that is active in the healthcare sector. The Company specializes in the development, marketing and distribution of healthcare products and services intended for healthcare professionals and institutions. It operates through the following segments: Essentials, enable pharmacists to compound safe products and optimize their compounding process with equipment and packaging. The portfolio includes pharmaceutical raw materials, compounding equipment, packaging, and supplies; Brands, focuses on developing semi-finished products and pharmaceutical-grade vehicles and reduce the workload for pharmacists; Compounding Services, utilizes raw materials from the Essentials segment and vehicles from the Brands segment for compounding activities, offering both sterile and non-sterile compounded products tailored to patients' specific needs.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Fagron NV revenues increased 11% to EUR476.1M. Net income increased 13% to EUR45.6M. Revenues reflect Fagron North America segment increase of 16% to EUR212.4M, Fagron Europe segment increase of 9% to EUR176.9M. Net income benefited from Other Operating Income increase from EUR1.2M to EUR3.6M (income). Basic Earnings per Share excluding Extraordinary Items increased from EUR0.55 to EUR0.62.



  • Poslední aktualizace: 18.02.2026
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Executive Chairman of the Board, Global Chief Scientific and Medical OfficerPatrick Soon-Shiong7111.08.2021
President, Chief Executive Officer, DirectorRichard Adcock5629.03.202126.10.2020
Chief Financial OfficerDavid Sachs4705.03.202105.03.2021
Chief Corporate Affairs, DirectorBarry Simon6009.03.202101.01.2007